Anti-CD20 (rituximab biosimilar) mAb
| Common Name |
MS4A1,CD20,MS4A-1 |
|---|---|
| Buffer |
Preservative: 0.1% Procline 300 Constituents: 50% Glycerol; PBS, pH 7.4; 0.1% BSA |
| Guarantee | 12 months from date of dispatch |
| Catalog Number | BME100025 |
|---|---|
| Package | 50 μl $80.00 ; 100 μl $160.00 |
| Synonyms | B1; Bp35; CD20; CVID5; LEU-16; MS4A2; S7 |
| Host Species | Chimeric |
| IgG type | IgG1 |
| Clonality | Monoclonal |
| Formulation | Liquid |
| Purification | Purified from cell culture supernatant by affinity chromatography |
| Reactivity | Human |
| Applications | Flow Cyt |
| Recommended Dilutions | Flow Cyt 1:100 |
| Storage | Store at -20°C (Avoid repeated freezing and thawing) |
| Usage | Research use only |
| Images |
Figure 1. HEK293 cell line transfected with irrelevant protein (B) and human CD20 protein (A) were surface stained with anti-CD20 neutralizing antibody 1μg/ml (rituximab) followed by Alexa 488-conjugated anti-human IgG secondary antibody. |
| Background | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. |
| Datasheet | Download | COA | Download |
|---|---|---|---|
| MSDS | Download | ||
简体中文
English
